Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active N-terminal fragment of endogenous human growth hormone-releasing hormone, GHRH(1-29)-NH2. This fragment retains the full GH-releasing activity of the parent 44-residue hormone, making Sermorelin one of the most established GHRH-analog research tools for probing pulsatile growth-hormone secretion from the anterior pituitary.
In laboratory model systems, Sermorelin binds and activates the GHRH receptor, triggering cAMP-mediated signaling and GH release. Because it acts at the physiological GHRH receptor rather than the ghrelin receptor, it is frequently used as a reference GHRH agonist in studies comparing GHRH-axis and secretagogue pathways. Supplied as a lyophilized powder for research use only.
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
Research on Sermorelin established that the GHRH(1-29) fragment is sufficient to reproduce the GH-releasing activity of full-length GHRH, providing a compact and synthetically tractable tool for GH-axis studies. In model systems it produces GHRH-receptor-mediated GH secretion with a short half-life, reflecting rapid enzymatic degradation of the unmodified sequence.
Comparative studies frequently use Sermorelin as the native-sequence reference against which DPP-IV-resistant and albumin-conjugated GHRH analogs are evaluated, highlighting how backbone modifications alter half-life and secretory pattern relative to the parent fragment.
Sermorelin (GHRH 1-29) was characterized in the 1980s following isolation and sequencing of human GHRH, and its acetate salt was later developed as a diagnostic and therapeutic GHRH agonist. It remains one of the most extensively studied GHRH-class peptides in the published literature and a standard reference tool in growth-hormone research.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. Sermorelin is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
